Actinium names Matt David, M.D. as chief financial officer
Actinium Pharmaceuticals said Matt David, who previously served as CFO and chief business officer at CorMedix, began as CFO on October 14, 2026.
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced on October 15, 2026 that Matt David, M.D. had become the company's Chief Financial Officer, effective October 14, 2026, according to an 8-K filed with the SEC. Dr. David, age 49, commenced service as Chief Financial Officer and principal financial officer of the company on October 14, 2026.1 He will oversee the company's finance, accounting, capital markets and investor relations work in his new principal financial officer role, per the filing.
Dr. David joins from CorMedix Inc. (Nasdaq: CRMD). He served as CorMedix's Chief Financial Officer from May 2020 to September 2025 and then as its Chief Business Officer through October 2026, having also served as Interim Chief Executive Officer from October 2021 to May 2022.1 In his roles there, he was responsible for finance, capital markets, investor relations and IT, and he helped the company complete its 2025 acquisition of Melinta Therapeutics as part of an effort to broaden its commercial business.1 During his tenure, CorMedix received FDA approval of DefenCath in 2023 and launched it commercially in 2024.1
Earlier in his career, Dr. David served as Head of Strategy at Ovid Therapeutics Inc. and spent more than a decade in healthcare investment banking at firms including BofA Merrill Lynch, Thomas Weisel Partners and Piper Jaffray, as well as in equity research at Lehman Brothers covering the pharmaceutical sector.1 He holds an M.D. from New York University School of Medicine and a B.A. from Dartmouth College.1
Under his offer letter dated September 30, 2026, Dr. David's compensation package includes a $450,000 annual base salary, a target bonus equal to 40% of salary, and a $150,000 signing bonus.1 He also received options for 250,000 shares and 325,000 restricted stock units under the company's 2026 Employment Inducement Award Plan.1 The options are priced at the stock's closing price on the grant date and vest over four years, while the RSUs carry both time-based and performance-based vesting tied to company milestones.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.